Protein-Based COVID-19 Vaccine Candidate Delays Advanced Research

In COVID-19, Latest News by Precision Vaccinations

Sanofi and GSK announce a delay in their adjuvanted recombinant protein-based COVID-19 vaccine program to improve immune response in older adults. 
This decision was published on December 11, 2020, and was based on the Phase 1/2 study interim results which showed an immune response comparable to patients who recovered from COVID-19 in adults aged 18 to 49 years. 
But, a low immune response in older adults, likely due to an insufficient concentration of the antigen, stated the companies.

Read More